BIOMAT Database Logo BIOMAT Database Logo

Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates. 2000

P Vanhems, and R Gaudet, and B Hirschel, and A Imrie, and B Conway, and D Rouleau, and J Vizzard, and L Perrin, and D A Cooper, and S Yerly

UI MeSH Term Description Entries
D008297 Male Males
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

P Vanhems, and R Gaudet, and B Hirschel, and A Imrie, and B Conway, and D Rouleau, and J Vizzard, and L Perrin, and D A Cooper, and S Yerly
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.
October 1993, Annals of internal medicine,
P Vanhems, and R Gaudet, and B Hirschel, and A Imrie, and B Conway, and D Rouleau, and J Vizzard, and L Perrin, and D A Cooper, and S Yerly
Primary infection with zidovudine-resistant HIV.
October 1993, The New England journal of medicine,
P Vanhems, and R Gaudet, and B Hirschel, and A Imrie, and B Conway, and D Rouleau, and J Vizzard, and L Perrin, and D A Cooper, and S Yerly
Primary infection with zidovudine-resistant HIV.
October 1993, The New England journal of medicine,
P Vanhems, and R Gaudet, and B Hirschel, and A Imrie, and B Conway, and D Rouleau, and J Vizzard, and L Perrin, and D A Cooper, and S Yerly
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
May 1993, Annals of internal medicine,
P Vanhems, and R Gaudet, and B Hirschel, and A Imrie, and B Conway, and D Rouleau, and J Vizzard, and L Perrin, and D A Cooper, and S Yerly
Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV.
January 1992, AIDS (London, England),
P Vanhems, and R Gaudet, and B Hirschel, and A Imrie, and B Conway, and D Rouleau, and J Vizzard, and L Perrin, and D A Cooper, and S Yerly
Transmission of zidovudine-resistant HIV-1.
December 1993, AIDS (London, England),
P Vanhems, and R Gaudet, and B Hirschel, and A Imrie, and B Conway, and D Rouleau, and J Vizzard, and L Perrin, and D A Cooper, and S Yerly
Clinical response to dideoxyinosine in patients with HIV infection resistant to zidovudine.
July 1990, The New England journal of medicine,
P Vanhems, and R Gaudet, and B Hirschel, and A Imrie, and B Conway, and D Rouleau, and J Vizzard, and L Perrin, and D A Cooper, and S Yerly
Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
May 1995, Archives of internal medicine,
P Vanhems, and R Gaudet, and B Hirschel, and A Imrie, and B Conway, and D Rouleau, and J Vizzard, and L Perrin, and D A Cooper, and S Yerly
Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.
March 1993, Journal of virological methods,
P Vanhems, and R Gaudet, and B Hirschel, and A Imrie, and B Conway, and D Rouleau, and J Vizzard, and L Perrin, and D A Cooper, and S Yerly
Zidovudine resistant HIV.
April 1989, BMJ (Clinical research ed.),
Copied contents to your clipboard!